# CoImmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coimmune

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.coimmune.com
- Total disclosed funding: $45M
- Latest round: Series A (Nov 4, 2020)
- Investors on record: 7

## About

Based in North Carolina, US, and founded in 2019, CoImmune Inc., a.k.a. CoImmune operates as a bio-venture company that is developing various anti-cancer pipelines based on CAR-T immune cells by leveraging its two cellular platform technologies. In November 2020, Colmmune, Inc. raised USD 45 million from Brain Asset Management, DS Asset Management, DSC Investment, Fidim S.r.l., Korea Investment Partners, Magna Investments, and W asset management. As of January 2023, Charles A. Nicolette is the CEO of the company.

The company’s product line includes CARCIK (chimeric antigen receptor cytokine-induced killer)-CD19 (CMN-005), CMN-008, CAR-CIK, bi-specific CAR-CIK (AMN-006), and DC (CMN-001). CoImmune is developing CAR-CIK technology for liquid tumors and our RNA-loaded dendritic cell technology for solid tumors. As of January 2023, the firm’s CAR-CIK product is currently in clinical trials in pediatric and adult acute lymphoblastic leukemia and its dendritic cell product is in a clinical trial in advanced metastatic renal cell carcinoma.

## Funding rounds

- Series A, Nov 4, 2020, $45M — Korea Investment Partners, DSC Investment, Brain Asset Management, Magna Investment, Fidim, W asset management, DS Asset Management

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- Brain Asset Management (https://capitalatlas.ai/funds/brain-asset-management) — Series A
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series A
- Fidim — Series A
- W asset management — Series A
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series A